Daniel Barber
2021
In 2021, Daniel Barber earned a total compensation of $1.2M as Chief Operating Officer at Aquestive Therapeutics, a 38% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $301,272 |
|---|---|
| Option Awards | $406,820 |
| Salary | $424,058 |
| Other | $24,953 |
| Total | $1,157,103 |
Barber received $424.1K in salary, accounting for 37% of the total pay in 2021.
Barber also received $301.3K in non-equity incentive plan, $406.8K in option awards and $25K in other compensation.
Rankings
In 2021, Daniel Barber's compensation ranked 8,263rd out of 12,415 executives tracked by ExecPay. In other words, Barber earned more than 33.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,263 out of 12,415 | 33rd |
Division Manufacturing | 3,655 out of 5,508 | 34th |
Major group Chemicals And Allied Products | 1,626 out of 2,378 | 32nd |
Industry group Drugs | 1,446 out of 2,099 | 31st |
Industry Pharmaceutical Preparations | 1,075 out of 1,549 | 31st |
Source: SEC filing on April 29, 2022.
Barber's colleagues
We found two more compensation records of executives who worked with Daniel Barber at Aquestive Therapeutics in 2021.
News
Aquestive Therapeutics CEO Daniel Barber's 2023 pay jumps 88% to $2.5M
April 26, 2024
Aquestive Therapeutics CEO Keith Kendall's 2021 pay jumps 59% to $2M
April 29, 2022
Aquestive Therapeutics CFO John Maxwell's 2020 pay jumps 24% to $1.3M
May 5, 2021
Aquestive Therapeutics CEO Keith Kendall's 2019 pay falls 67% to $2.6M
April 29, 2020